Phase III clinical study of BAY 12-8039 (moxifloxacin) for respiratory tract infections

Japanese Journal of Chemotherapy

Volumn 53, Issue SUPPL. 3, 2005, Pages 47-59

  Kobayashi, Hiroyuki ^a   Aoki, Nobuki ^b   Niki, Yoshihito ^c   Watanabe, Akira ^d   Kawai, Shin ^e   Odagiri, Shigeki ^f,j   Kohno, Shigeru ^g   Yamaguchi, Keizo ^h   Saito, Atsushi ^i,k  

^a KYORIN UNIVERSITY   (Japan)

^b Shinrakuen Hospital   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^g NAGASAKI UNIVERSITY   (Japan)

^h TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF THE RYUKYUS   (Japan)

^j YOKOHAMA CITY UNIVERSITY   (Japan)

^k Japanese Red Cross Society   (Japan)

more..

Author keywords

Clinical trial; Moxifloxacin; Respiratory tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AMYLASE; AZITHROMYCIN; CEFUROXIME AXETIL; CLARITHROMYCIN; CREATINE KINASE; GATIFLOXACIN; LEVOFLOXACIN; LIVER ENZYME; MOXIFLOXACIN; NEW DRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TOSUFLOXACIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; EOSINOPHILIA; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MYCOPLASMA PNEUMONIA; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PHASE 3 CLINICAL TRIAL; RASH; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SUPERINFECTION; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; VOMITING;

EID: 30344465725     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chinesse source. 33:1029-1045, 2005
2. Wise R: A Review of the Clinical Pharmacology of Moxifloxacin, a New 8-Methoxyquinolone, and its Potential Relation to Therapeutic Efficacy. Clin Drug invest 17: 365-387, 1999
3. Stass H, Kubitza D, Halabi A, et al: Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 53: 232-237, 2002
4. Soman A, Honeybourne D, Andrews J, et al: Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 44: 835-838, 1999
5. Stass H, Kubitza D: Profile of moxifloxacin drug interactions. Clin Infect Dis 32 (Suppl 1): S47-50, 2001
6. Hoeffken G, Meyer H P, Winter J, et al: The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 95: 553-564, 2001
7. Petitpretz P, Arvis P, Marel M, et al: Oral moxifloxacin vs High-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired pneumonia in adults. Chest 119: 185-195, 2001
8. Patel T, Pearl J, Williams J, et al: Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Respir Med 94: 97-105, 2000
9. Wilson R, Kubin R, Ballin I, et al: Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 44: 501-513, 1999
10. Chodosh S, DeAbate C A, Haverstock D, et al: Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 94: 18-27, 2000
11. Parish L C, Routh H B, Miskin B, et al: Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 54: 497-503, 2000
12. Siegert R, Gehanno P, Nikolaidis P, et al: A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 94: 337-344, 2000
13. Chinesse source.
14. Chinesse source. 45:762-778, 1997
15. Chinesse source. Chemotherapy 29: 76-79, 1981
16. Chinesse source. 2005
17. DeAbate C A, Mathew C P, Warner J H, et al: The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 94: 1029-1037, 2000
18. Schaberg T, Ballin I, Huchon G, et al: A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiv oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Research 29: 314-328, 2001
19. Hautamaki D, Bruya T, Kureishi A, et al: Short-course (5-day) moxifloxacin versus 7-day leveofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. In Today's Therapeutic Trends, p. 117-136, Communication Media for Education, Princeton Jundction, NJ, 2001
20. Kreis S R, Nerrera N, Golzar N, et al: A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcome Management 7: 33-37, 2000
21. Wilson R, Allegra L, Huchon G, et al: Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbation of chronic bronchitis. Chest 125: 953-964, 2004
22. Andes D, Craig W: Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19: 261-268, 2002
23. Zhao X, Drlica K: Restricting the selection of antibiotic-resistance mutant bacteria: Measurement and potential use of the mutant selection window. J Infect Dis 185: 561-565, 2002
24. Blondeau J M, Zhao X, Hansen G, et al: Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45: 433-438, 2001
25. Firsov A A, Vostrov S N, Lubenko I Y, et al: In vitro pharmacokinetic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agencts Chemother 47: 1604-1613, 2003
26. Zinner S H, Lubenko I Y, Gilbert D, et al: Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52: 616-622, 2003